37 results about "Cholesteryl ester" patented technology

Provided herein are methods and materials for using organisms (e.g., engineered yeast strain-derived) to generate lipid compositions which can modulate cellular aging, extend lifespan, and / or modulate gut homeostasis in a subject. The lipid compositions contain at least twelve of the lipids selected from a phosphatidylethanolamine (PE); a lysophosphatidylethanolamine (LPE); a diacylglycerol (DG); a monoglyceride (MG); an acyl carnitine (AcCa); a phosphatidic acid (PA); a phosphatidylglycerol (PG); a lysophosphatidylcholine (LPC); a triacylglycerol (TG); a cholesterol ester (ChE); a wax ester (WE); a phosphatidylserine (PS); a phosphatidylcholine (PC); a phosphatidylinositol (PI); a ceramide (Cer); and a lysophosphatidylserine (LPS).

The invention relates to the technical field of biotechnology and medical detection, in particular to an ovarian cancer early-stage accurate screening method based on triple lipid metabolite chemical crosslinking, which comprises the following steps: sample collection: collecting a serum sample of a person to be detected; lipid metabolite extraction: extracting lipid metabolite from the serum sample; detection of triple lipid metabolites: simultaneously detecting the contents of sphingomyelin (SM), phosphatidylcholine (PC) and cholesteryl ester (CE) in the lipid metabolites by adopting a liquid chromatography-mass spectrometry technology, and by simultaneously detecting the three lipid metabolites of sphingomyelin (SM), phosphatidylcholine (PC) and cholesteryl ester (CE) and carrying out chemical cross-linking analysis, the content of the triple lipid metabolites in the lipid metabolites can be detected; and calculating the triple lipid metabolite index (TLMI), so that the abnormal lipid metabolism condition of the ovarian cancer patient can be more comprehensively and accurately reflected, and the sensitivity and the specificity of early screening of the ovarian cancer are improved.

The invention provides a method and a device for secondary filtration and re-removal of cholesterol ester after continuous blood purification and blood fat filtration, and belongs to the technical field of medical blood purification. According to the method and the device, the technology of combining enzymolysis, adsorption and membrane separation is adopted for residual CE in a CBP filtering product. The method comprises the following steps: firstly, decomposing CE into small molecules by using specific enzyme, and weakening the combination of CE and other components; residual impurities are further adsorbed through a high-performance adsorption material; and finally, efficient removal of CE is realized by virtue of a high-precision membrane separation technology, so that the residual quantity is reduced to be below a safety threshold value. Compared with a traditional technology, the problems that the CE-containing filtrate is high in recycling risk and low in resource utilization rate are effectively solved, the purity of a filtered product is remarkably improved, technical support is provided for industrial scenes such as plasma exchange, filtrate feedback, biopharmacy and extracorporeal circulation in the medical field, and the application prospect is wide. The safety and the resource utilization efficiency of the blood purification technology are promoted.

This invention relates to the field of biomedical technology, specifically to a polyethylene glycol-modified liposome loaded with dimethylcurcumin and its preparation method. First, cholesterol is reacted with succinic anhydride to obtain cholesterol monosuccinate. Then, the cholesterol monosuccinate is coupled with polyethylene glycol via an ester bond to synthesize polyethylene glycol-cholesterol. Using polyethylene glycol-cholesterol, polyethylene glycol monostearate, and lecithin as the main components, and dimethylcurcumin as the model drug, polyethylene glycol-modified dimethylcurcumin liposomes are prepared using a thin-film hydration method. These liposomes exhibit high encapsulation efficiency. In vitro simulated drug release experiments show that these liposomes can improve the sustained-release effect of dimethylcurcumin. Cytotoxicity experiments also demonstrate that the polyethylene glycol-modified dimethylcurcumin liposomes possess good antitumor activity.

This invention discloses a gRNA combination and its application in the preparation of drugs for the prevention of metabolic-associated fatty liver disease (MASLD). The gRNA combination, when mixed with Cas9 protein, yields an RNP complex, which, when microinjected into mouse zygotes, can breed a stable and heritable mouse strain with TMEM68 gene knockout. Combining lipidomics, transcriptomics, and primary hepatocyte functional verification, the core regulatory role of TMEM68 in hepatic lipid metabolism is revealed for the first time systematically. Experiments demonstrate that TMEM68 deficiency significantly reduces the storage of triglycerides (TAG) in the liver and hepatocytes, decreases lipid droplet formation, and reshapes the metabolic homeostasis of various lipids such as glycerophospholipids, cholesterol esters, and bile acids. Therefore, the gRNA combination of this invention, or the RNP complex obtained by mixing the gRNA combination with Cas9 protein, can be used to prepare drugs for the prevention of MASLD, providing a novel intervention strategy for MASLD prevention with broad application prospects.

The invention relates to the technical field of specific therapeutic activity of pharmaceutical preparations, in particular to application of Avasimibe in preparation of drugs for treating pulmonary fibrosis. The invention relates to an application of Avasimibe in preparation of a medicine for treating pulmonary fibrosis. The Avasimibe is used for reducing the generation of foam cells by targeting SOAT1 so as to relieve the occurrence and development of pulmonary fibrosis. The invention reveals that Avasimibe can reduce the generation of foam cells by targeting SOAT1 so as to relieve the occurrence and development of pulmonary fibrosis. Meanwhile, it is also elaborated that Avasimibe can restore the steady state of cholesterol and cholesteryl ester, improve the fluidity of a cell membrane structure and restore the lipophagy function, and the invention develops the application of Avasimibe in treatment of pulmonary fibrosis diseases.

The present invention is directed to a cargo-loaded cholesteryl ester nanoparticle with a hollow compartment (“cholestosome”) consisting essentially of at least one non-ionic cholesteryl ester and one or more encapsulated active molecules which cannot appreciably pass through an enterocyte membrane in the absence of said molecule being loaded into said cholestosome, the cholestosome having a neutral surface and having the ability to pass into enterocytes in the manner of orally absorbed nutrient lipids using cell pathways to reach the golgi apparatus. Pursuant to the present invention, the novel cargo loaded cholestosomes according to the present invention are capable of depositing active molecules within cells of a patient or subject and effecting therapy or diagnosis of the patient or subject.

A new class of synthetic cyclodextrin dimers is described. Exemplary cyclodextrin dimers are capable of treating atherosclerotic plaques by targeting various forms of cholesterol both intracellularly and extracellularly. Methods of depleting atherosclerotic plaques of cholesterol, cholesterol esters, 7-ketocholesterol, and 7-ketocholesterol esters by treatment with such cyclodextrins are also provided. A sub-class of dimers with high specificity for 7-ketocholesterol is also described.

The present invention relates to a cholesteryl ester transfer protein (CETP) inhibitor for use in the treatment of a subject suffering from or at an increased risk of cardiovascular disease, in particular hyperlipidemia or mixed dyslipidemia. Another aspect of the invention relates to a pharmaceutical composition for treating a subject suffering from or having an increased risk of cardiovascular disease, wherein the composition comprises a therapeutically effective amount of the CETP inhibitor.

The invention discloses a blood chyle degree detection reference and a preparation method thereof. The reference comprises the following components: triglyceride, cholesteryl ester, free cholesterol, phosphatidylcholine, bovine serum albumin, a buffer solution and an auxiliary agent. The blood chyle degree detection reference product provided by the invention can be stably stored, is low in cost, can be used for instrument calibration, can be used for judging and grading clinical plasma chyle degree and the like, and can unify detection standards and eliminate artificial interference; based on the blood chyle degree detection reference product provided by the invention, detection can be realized by utilizing image gray calculation, and compared with manual visual inspection, the detection accuracy is greatly improved.

The present invention relates to a cholesteryl ester transfer protein (CETP) inhibitor for use in the treatment of an individual suffering from or at increased risk of cardiovascular disease, in particular hyperlipidemia or mixed dyslipidemia. Another aspect of the invention relates to a pharmaceutical composition for use in the treatment of an individual suffering from or at increased risk of cardiovascular disease, wherein the composition comprises a therapeutically effective amount of the CETP inhibitor.

The present invention relates to a cholesteryl ester transfer protein (CETP) inhibitor:(Compound A) for use in the treatment of subjects suffering from or having an increased risk for cardiovascular diseases, in particular hyperlipidemia or mixed dyslipidemia. A further aspect of the present invention relates to a pharmaceutical composition for use in the treatment of subjects suffering from or having an increased risk for cardiovascular diseases, wherein the composition comprises a therapeutically effective amount of said Compound A CETP inhibitor.

The present invention provides a composition to increase tear production to relieve irritation from dry eyes, and a method for application of the composition. The composition includes at least 5% menthol and a carrier. The carrier comprises at least one of: a triglyceride oil, a medium chain triglyceride, petroleum jelly, coconut oil, olive oil, beeswax, a wax that is semi-solid at 21 C, a vegetable wax, an animal wax, a petroleum wax, a mineral wax, a synthetic wax, vaseline, lanoline, hydrogenated rosin / glyceryl diisostearate, hydrogenated polyisobutene, polyethylene, fatty acid cholesteryl, higher fatty acid esters, aliphatic alcohols, squalene, polyethyleneglycol, higher fatty acids, animal oil, and vegetable oil. The method includes delivering the composition to a user's eye.

The application provides a high-purity human Orai2 membrane protein preparation method based on a mammalian cell expression system. The method obtains a recombinant expression vector containing a human Orai2 gene and an affinity tag sequence; the recombinant expression vector is transfected into a host cell line for expression; a membrane dissolving buffer containing dodecyl-beta-D-maltopyranoside and cholesteryl hemisuccinate is used for lysis extraction of the host cell; after centrifugation to obtain supernatant, the supernatant is sequentially separated and purified by using an affinity chromatography medium and a gel exclusion chromatography medium, and high-purity human Orai2 protein is obtained. The application constructs a thermodynamic equilibrium micellar microenvironment, solves the conformational inactivation problem in the extraction process of multiple transmembrane proteins, and realizes efficient and high-purity enrichment of human Orai2 protein.

The application belongs to the technical field of biological medicine, and particularly relates to an N,N-dimethylethylene diamine-thiodiglycolic acid monocholesteryl ester conjugate as well as a preparation method and application thereof. The structural formula of the N,N-dimethylethylene diamine-thiodiglycolic acid monocholesteryl ester conjugate is as follows: first, cholesteryl and thiodiglycolic anhydride are dissolved together, N,N-dimethylaminopyridine is added, and a reflux reaction is performed to obtain thiodiglycolic acid monocholesteryl ester; then, 1-ethyl-(3-dimethylaminopropyl) carbodiimide hydrochloride is dissolved together, N,N-dimethylethylene diamine is added, and a reaction is performed to obtain a conjugate molecule. The conjugate is blended with lecithin to serve as a cationic liposome. By adjusting the ratio of lecithin and the conjugate, the particle size and potential of the cationic liposome can be adjusted.

Cholesteryl ester transfer protein inhibitors for use in the treatment or prevention of cardiovascular disease and pharmaceutical compositions containing the same. The present invention relates to cholesteryl ester transfer protein (CETP) inhibitors for use in the treatment of an individual suffering from or at increased risk of cardiovascular disease, in particular hyperlipidemia or mixed dyslipidemia. Another aspect of the invention relates to a pharmaceutical composition for use in the treatment of an individual suffering from or at increased risk of cardiovascular disease, wherein the composition comprises a therapeutically effective amount of the CETP inhibitor.

A nucleic acid-loaded calcium-containing cationic lipid nanoparticle, comprising a cationic lipid, a neutral lipid, a PEGylated lipid, and cholesterol and / or a cholesterol ester. The cationic lipid nanoparticle can be used for preparing a gene-based drug for local injection into the body or a nucleic acid vaccine for local or systemic injection into the body.

The invention relates to the technical field of medicines and cosmetics, in particular to a soothing and repairing composition and a preparation method thereof, in the composition, a bionic liquid crystal system simulates a lamellar liquid crystal structure of skin intercellular lipid, the affinity and permeability between an external preparation and the skin surface are enhanced, and the delivery efficiency of active ingredients is remarkably improved. A stable moisturizing film is rapidly formed on the skin surface, percutaneous moisture loss is effectively reduced, the dry state is improved, and the epidermis water steady state is recovered. The plant bionic sebum is highly similar to human body sebum by extracting and reasonably reconstructing plant-derived fatty acid, cholesteryl ester and soothing components, and participates in the skin immune regulation and inflammation relieving process through multiple biological activity approaches such as anti-inflammation, anti-oxidation and soothing, so that active repairing and strengthening of a barrier function are realized, and the skin is protected. The skin barrier repairing and water locking functions are enhanced. The product is safe and mild, is suitable for various skin types, and has a good application prospect in the technical fields of medicines and cosmetics.

Compositions and methods relating to ApoA-1 fusion polypeptides are disclosed. The fusion polypeptides include a first polypeptide segment corresponding to an ApoA-1 polypeptide or ApoA-1 mimetic, and may also include a dimerizing domain such as, e.g., an Fc region, which is typically linked carboxyl-terminal to the first polypeptide segment via a flexible linker. In some embodiments, the fusion polypeptide further includes a second polypeptide segment located carboxyl-terminal to the first polypeptide segment and which confers a second biological activity (e.g., an RNase, paraoxonase, platelet-activating factor acetylhydrolase, cholesterol ester transfer protein, lecithin-cholesterol acyltransferase, polypeptide that specifically binds to proprotein convertase subtilisin / kexin type 9, or polypeptide that specifically binds to amyloid beta). Also disclosed are dimeric proteins comprising first and second ApoA-1 fusion polypeptides as disclosed herein. The fusion polypeptides and dimeric proteins are useful in methods for therapy.

This invention relates to compositions and methods relating a combination of naturally-occurring active ingredients, including active agents unrelated to statins, useful for the regulation total blood cholesterol. The inventive combination of active ingredients, including policosanol, mevinolic acid from dry yeast extract of red rice, dry extract of Lespedeza captitata, and dry grape seed extract, interrupts or inhibits the metabolic pathway leading to biosynthesis of cholesterol and cholesterol ester at multiple points and may also reduce high triglyceride levels. The present invention may be used to achieve normal blood serum LDL cholesterol concentrations and establish a healthy balance between LDL and HDL, all while significantly reducing the risk of statin-related side effects.

The present disclosure relates to gene therapy compositions and methods for the preparation and use thereof, for the treatment of Lysosomal Acid Lipase Deficiency (LAL-D) disorders, such as Wolman Disease and cholesterol ester storage disease (CESD).

The present application belongs to the technical field of medicine, and mainly relates to a conjugate of an ApoA1 short peptide and a tubulin inhibitor and a self-assembled nano preparation thereof, wherein the ApoA1 short peptide and the tubulin inhibitor are coupled through a linker. The self-assembled nano preparation comprises the following components: 1-100 parts of the conjugate of the ApoA1 short peptide and the tubulin inhibitor; 1-100 parts of phospholipid; 1-100 parts of cholesteryl ester; and 1-100 parts of water for injection or phosphate buffer. The conjugate of the ApoA1 short peptide and the tubulin inhibitor improves the targeting of the tubulin inhibitor on tumor cells and reduces the toxic side effects of the tubulin inhibitor; the self-assembled nano preparation has the advantages of low cost, few operation steps, simple process, good repeatability, can realize efficient mass production at low cost, and is conducive to storage and drug administration.

The present invention relates to a method for determining the presence of Mycobacterium bovis in a subject. The method comprises: (i) determining the level of one or more biomarkers in a sample from the subject; and (ii) comparing the level of said one or more biomarkers with the level of said one or more metabolites in a control sample to determine whether Mycobacterium bovis is present in the subject. The biomarkers are selected from: dihydro-leukotriene B4, 3-hydroxyisovaleric acid, sphingomyelin [SM(d18:2(4E,14Z) / 24:0)], sphingomyelin [SM(d18:1 / 24:1(15Z))], 18:3 cholesteryl ester, an unknown compound 389.21933 m / z (under negative ionisation), an unknown compound 886.71063 m / z (under negative ionisation), citric acid, MG(0:0 / 18:3(6Z,9Z,12Z) / 0:0), pyrocatechol, N-(docosanoyl)-heptadecasphing-4-enine-1-phosphocholine and an unknown compound 359.22107 m / z (under negative ionisation).

The present invention relates to a method for determining the content of omega-3 polyunsaturated fatty acids in the retina of a subject comprising the determination of the content of at least one cholesteryl ester in a blood sample from said subject, the content of omega-3 polyunsaturated fatty acids in the retina being correlated to the content of said at least one cholesteryl ester, said at least one cholesteryl ester being cholesteryl 5,8,11,14,17-eicosapentaenoate.

The application relates to the field of skin care products and discloses a ceramide liposome for skin care products and a preparation method thereof, the ceramide liposome comprising the following components in parts by weight: 5-10 parts of hydrogenated lecithin, 0.5-2 parts of modified cholesterols, 0.5-2 parts of ceramides, 0.1-2.5 parts of sucrose stearate, 0.1-1 part of polyglyceryl-10 stearate and 15-30 parts of an organic solvent; the modified cholesterols are prepared by grafting glycine cholesterols and carboxymethyl chitosan through chemical reactions, the glycine cholesterols are prepared by taking cholesterols, N-tert-butoxycarbonylglycine and trifluoroacetic acid as raw materials, and the carboxymethyl chitosan is prepared by grafting chloroacetic acid and chitosan; the ceramide liposome with good stability and good skin barrier repair and moisturizing and water-locking effects is prepared by taking the hydrogenated lecithin, the modified cholesterols, the ceramides, the sucrose stearate and the polyglyceryl-10 stearate as raw materials.

The present application relates to a kind of low-density extracellular vesicles and its preparation method and application, the low-density extracellular vesicles is derived from CD4 + Chimeric antigen receptor T (CD4 + CAR-T) cell culture fluid, after obtaining supernatant by ultracentrifugation, again by ultrafiltration cut-off purification is obtained.The present application is first isolated and identified from CD4 + CAR-T cell a new type of low-density extracellular vesicles (LD-EVs), the subtype is missed in traditional EV separation process, and the cognition to EV diversity is widened.The characteristics of LD-EVs are rich in sterol ester (especially cholesterin ester) by lipidomics etc., which is related to its low-density characteristics and potential membrane stability, signal transmission function, provides target for functional research and engineering modification.

This invention discloses a composite nanozyme, its preparation method, and its application. The composite nanozyme uses Prussian blue nanoparticles as a carrier, with a phospholipid bilayer formed by dimyristoylphosphatidylcholine coated on the surface of the Prussian blue nanoparticles. The phospholipid bilayer contains (2,3-dioleoyl-propyl)-trimethylamine and undecylimidazole. This invention is the first to disclose a composite nanozyme formed by modifying the surface of Prussian blue nanoparticles with DOTAP and imidazole groups. The obtained composite nanozyme can effectively catalyze ester hydrolysis, producing at least two orders of magnitude acceleration, which provides a possibility for the direct hydrolysis of cholesterol esters in atherosclerotic plaques by nanomedicines. This invention expands the enzyme-like activity of the Prussian blue nanozyme through special modification, providing a solution for simultaneously achieving multifunctional composite nanozymes with ester hydrolytic enzyme function, catalase-like properties, and superoxide dismutase-like properties.

The present invention relates to a cholesteryl ester transfer protein (CETP) inhibitor for use in the treatment of an individual suffering from or at increased risk of cardiovascular disease, in particular hyperlipidemia or mixed dyslipidemia. Another aspect of the invention relates to a pharmaceutical composition for use in the treatment of an individual suffering from or at increased risk of cardiovascular disease, wherein the composition comprises a therapeutically effective amount of the CETP inhibitor.

The invention discloses bionic skin lipid and a preparation method thereof. The compound vegetable oil composed of the deep sea fish oil, the camellia seed oil and the prinsepia utilis royle oil is selected, and is rich in triacylglycerol, phytosphingosine, squalene, cholesteryl ester, cholesterol, wax ester, phospholipid and other lipids required by skin; candida lipolytica is adopted to ferment the compound vegetable oil, the bionic skin lipid is obtained after fermentation, the content of effective components and the use feeling are obviously improved, and the bionic skin lipid can be used as an active component to be added into a cosmetic matrix. The multi-dimensional effects of maintaining a skin barrier function, preserving moisture, resisting inflammation, regulating micro-ecology and the like are achieved.

Compositions and methods relating to ApoA-1 fusion polypeptides are disclosed. The fusion polypeptides include a first polypeptide segment corresponding to an ApoA-1 polypeptide or ApoA-1 mimetic, and may also include a dimerizing domain such as, e.g., an Fc region, which is typically linked carboxyl-terminal to the first polypeptide segment via a flexible linker. In some embodiments, the fusion polypeptide further includes a second polypeptide segment located carboxyl-terminal to the first polypeptide segment and which confers a second biological activity (e.g., an RNase, paraoxonase, platelet-activating factor acetylhydrolase, cholesterol ester transfer protein, lecithin-cholesterol acyltransferase, polypeptide that specifically binds to proprotein convertase subtilisin / kexin type 9, or polypeptide that specifically binds to amyloid beta). Also disclosed are dimeric proteins comprising first and second ApoA-1 fusion polypeptides as disclosed herein. The fusion polypeptides and dimeric proteins are useful in methods for therapy.